Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of decitabine + venetoclax for AML secondary to myeloproliferative neoplasms in patients unfit for intensive chemotherapy
2020-006114-20Phase 2Active
- Sponsor
- GIMEMA
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and decitabine in Post-myeloproliferative neoplasms acute myeloid leukemia, sponsored by GIMEMA. Primary endpoint: Event-free survival at 1 year. Started Jul 2021; status: active.
02
Drugs
venetoclaxdecitabine
03
Conditions
Post-myeloproliferative neoplasms acute myeloid leukemia
Beyond the preview
Go deeper on 2020-006114-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006114-20.